PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-7.40%
Negative ROE while Healthcare median is -4.32%. Seth Klarman would investigate if capital structure or industry issues are at play.
-6.83%
Negative ROA while Healthcare median is -4.03%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-7.50%
Negative ROCE while Healthcare median is -4.21%. Seth Klarman would investigate whether a turnaround is viable.
85.43%
Gross margin exceeding 1.5x Healthcare median of 37.87%. Joel Greenblatt would see if cost leadership or brand drives the difference.
-549.36%
Negative operating margin while Healthcare median is 0.00%. Seth Klarman would look for a path to operational turnaround.
-541.91%
Negative net margin while Healthcare median is 0.00%. Seth Klarman would see if cost cuts or revenue growth can fix losses.